Literature DB >> 20582959

Effect of L-arginine supplementation on immune responsiveness in patients with sickle cell disease.

Arnette Scavella1, Lily Leiva, Hanh Monjure, Arnold H Zea, Renee V Gardner.   

Abstract

BACKGROUND: L-arginine (L-Arg) is deficient in sickle cell disease (SSD) during vasoocclusion. We investigated possible causal relationship between L-Arg deficiency and immune dysfunction in SSD in steady-state. PROCEDURE: Fifteen patients with SSD in steady-state and 13 controls were studied. Plasma L-Arg levels were measured using liquid chromatography. T cell subsets and CD3zeta (CD3zeta) chain expression were analyzed using flow cytometry. Lymphocyte proliferative response to phytohemagglutinin (PHA) and production of IL-6 and interferon-gamma (IFN-gamma) were evaluated with and without L-Arg.
RESULTS: SSD patients had significantly lower L-Arg levels than controls. CD3 and CD19 cell populations were comparable for both groups, but SSD patients had above normal numbers of natural killer cells (P = 0.06). Patients and controls exhibited significantly increased lymphocyte blastogenesis to PHA after introduction of L-Arg to cultures; response of patients was significantly greater than values for control individuals. Proliferative response to candida in SSD patients was significantly lower than in controls; L-Arg supplementation did not increase this response. L-Arg had no effect on blastogenic response to PPD and candida albicans. No effect was likewise seen in production of IL-6 and IFN-gamma after addition of L-Arg. CD3zeta chain expression increased after addition of L-Arg in both groups; differences were insignificant.
CONCLUSION: L-Arg levels in steady-state SSD are significantly lower than in controls. L-Arg supplementation enhanced lymphocyte blastogenesis to PHA for both controls and patients, but not in response to antigen. There were no significant differences in CD3zeta chain expression although upregulation of expression occurred after L-Arg supplementation for both groups. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20582959     DOI: 10.1002/pbc.22562

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  2 in total

Review 1.  Arginases and arginine deficiency syndromes.

Authors:  Sidney M Morris
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2012-01       Impact factor: 4.294

2.  Citrulline Supplementation Improves Organ Perfusion and Arginine Availability under Conditions with Enhanced Arginase Activity.

Authors:  Karolina A P Wijnands; Dennis M Meesters; Kevin W Y van Barneveld; Ruben G J Visschers; Jacob J Briedé; Benjamin Vandendriessche; Hans M H van Eijk; Babs A F M Bessems; Nadine van den Hoven; Christian J H von Wintersdorff; Peter Brouckaert; Nicole D Bouvy; Wouter H Lamers; Anje Cauwels; Martijn Poeze
Journal:  Nutrients       Date:  2015-06-29       Impact factor: 5.717

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.